Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1075618.RAde8tGMTuypsFQ8_lZ92RsgthFgLpy77gmjLePyupD8c130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1075618.RAde8tGMTuypsFQ8_lZ92RsgthFgLpy77gmjLePyupD8c130_assertion type Assertion NP1075618.RAde8tGMTuypsFQ8_lZ92RsgthFgLpy77gmjLePyupD8c130_head.
- NP1075618.RAde8tGMTuypsFQ8_lZ92RsgthFgLpy77gmjLePyupD8c130_assertion description "[The availability of emerging compounds with antagonistic activity to microRNAs in the clinic provides the opportunity for future therapeutic targeting of miR-155 in AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1075618.RAde8tGMTuypsFQ8_lZ92RsgthFgLpy77gmjLePyupD8c130_provenance.
- NP1075618.RAde8tGMTuypsFQ8_lZ92RsgthFgLpy77gmjLePyupD8c130_assertion evidence source_evidence_literature NP1075618.RAde8tGMTuypsFQ8_lZ92RsgthFgLpy77gmjLePyupD8c130_provenance.
- NP1075618.RAde8tGMTuypsFQ8_lZ92RsgthFgLpy77gmjLePyupD8c130_assertion SIO_000772 23650424 NP1075618.RAde8tGMTuypsFQ8_lZ92RsgthFgLpy77gmjLePyupD8c130_provenance.
- NP1075618.RAde8tGMTuypsFQ8_lZ92RsgthFgLpy77gmjLePyupD8c130_assertion wasDerivedFrom befree-2016 NP1075618.RAde8tGMTuypsFQ8_lZ92RsgthFgLpy77gmjLePyupD8c130_provenance.
- NP1075618.RAde8tGMTuypsFQ8_lZ92RsgthFgLpy77gmjLePyupD8c130_assertion wasGeneratedBy ECO_0000203 NP1075618.RAde8tGMTuypsFQ8_lZ92RsgthFgLpy77gmjLePyupD8c130_provenance.